Blocking of monocyte chemoattractant protein-1 during tubulointerstitial nephritis resulted in delayed neutrophil

Ping Li1, Gabriela E Garcia, Yiyang Xia

  • 1Department of Medicine, Renal and Infectious Disease Sections, Baylor College of Medicine, Houston, TX 77030. lfeng@bcm.tmc.edu

Insights

Monocyte chemoattractant protein-1 (MCP-1) drives kidney inflammation in tubulointerstitial nephritis (TIN). Blocking MCP-1 with antibodies or antagonists reduced macrophage infiltration but delayed neutrophil clearance in TIN rat models.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Monocyte chemoattractant protein (MCP)-1 is linked to monocyte/macrophage infiltration in tubulointerstitial nephritis (TIN).
  • Understanding MCP-1's role is crucial for developing targeted therapies for TIN.

Purpose of the Study:

  • To investigate the specific role of MCP-1 in the pathogenesis of TIN in a rat model.
  • To evaluate the therapeutic potential of neutralizing MCP-1 activity in TIN.

Main Methods:

  • Administration of a neutralizing anti-MCP-1 antibody (Ab) and a peptide-based MCP-1 receptor antagonist (RA) in TIN rat models.
  • Assessment of macrophage infiltration and neutrophil clearance in kidney tissues.
  • In vitro assays to examine MCP-1's effect on macrophage-mediated phagocytosis.
  • Immunoprecipitation and pull-down assays to confirm antibody-antigen binding.

Main Results:

  • Treatment with anti-MCP-1 Ab significantly reduced macrophage infiltration in TIN rat kidneys.
  • Neutrophil clearance was delayed in TIN model rats treated with either anti-MCP-1 Ab or MCP-1 RA.
  • MCP-1 did not directly impair macrophage phagocytosis of neutrophils in vitro.
  • The anti-MCP-1 Ab formed immune complexes with heparan sulfate-immobilized MCP-1 in the kidneys.

Conclusions:

  • MCP-1 induction correlates with leukocyte infiltration in TIN.
  • MCP-1 antagonism, via antibody or receptor antagonist, alters TIN pathology, potentially by delaying apoptotic neutrophil removal.
  • Targeting MCP-1 presents a potential therapeutic strategy for managing TIN.